The Matter of Clinical Sequencing for Familial Breast Cancer: The route from Sanger to Next Generation

被引：0

作者：

Eryilmaz, Isil Ezgi ^{[1
]}

Eskiler, Gamze Guney ^{[2
]}

Cecener, Gulsah ^{[1
]}

Egeli, Unal ^{[1
]}

Tunca, Berrin ^{[1
]}

机构：

[1] Uludag Univ, Dept Med Biol, Fac Med, Bursa, Turkey

[2] Sakarya Univ, Dept Med Biol, Fac Med, Sakarya, Turkey

来源：

2017 IEEE INTERNATIONAL CONFERENCE ON E-HEALTH AND BIOENGINEERING CONFERENCE (EHB) | 2017年

关键词：

Familial breast cancer; Sanger sequencing; next generation sequencing; EARLY-ONSET; INHERITED MUTATIONS; DNA-REPAIR; RISK; BRCA1; ASSOCIATION; VARIANTS; PALB2;

D O I：

暂无

中图分类号：

TP39 [计算机的应用];

学科分类号：

081203 ; 0835 ;

摘要：

We mentioned the importance of clinical sequence analysis in risk determination, diagnostic and therapeutic process of familial breast cancer and we also summarized next generation sequencing applications in this cancer type. In conclusion, BRCA1/2 genes mutations are associated with an increasing the risk of particularly familial breast cancer. However, sequencing of moderate penetrance genes and/or whole exome could also fill large knowledge gaps in explaining genetic predisposition of breast cancer.

引用

页码：181 / 184

页数：4

共 50 条

[21] Next generation sequencing in cancer research and clinical application
Derek Shyr
Qi Liu
Biological Procedures Online, 15
[22] Next Generation Sequencing in Clinical Environment for Cancer Therapy
Lee, B.
Choi, Y-L
Park, H. Y.
Ko, Y. H.
LABORATORY INVESTIGATION, 2013, 93 : 435A - 436A
[23] Next generation sequencing in cancer research and clinical application
Shyr, Derek
Liu, Qi
BIOLOGICAL PROCEDURES ONLINE, 2013, 15
[24] Next Generation Sequencing in Clinical Environment for Cancer Therapy
Lee, B.
Choi, Y-L
Park, H. Y.
Ko, Y. H.
MODERN PATHOLOGY, 2013, 26 : 435A - 436A
[25] Clinical Next Generation Sequencing for Precision Medicine in Cancer
Dong, Ling
Wang, Wanheng
Li, Alvin
Kansal, Rina
Chen, Yuhan
Chen, Hong
Li, Xinmin
CURRENT GENOMICS, 2015, 16 (04) : 253 - 263
[26] The antibody genetics of multiple sclerosis: comparing next-generation sequencing to Sanger sequencing
Rounds, William H.
Ligocki, Ann J.
Levin, Mikhail K.
Greenberg, Benjamin M.
Bigwood, Douglas W.
Eastman, Eric M.
Cowell, Lindsay G.
Monson, Nancy L.
FRONTIERS IN NEUROLOGY, 2014, 5
[27] Cost analysis of standard Sanger sequencing versus next generation sequencing in the ICONIC study
Patel, Nishma
Ferns, Bridget R.
Nastouli, Eleni
Kozlakidis, Zisis
Kellam, Paul
Morris, Stephen
LANCET, 2016, 388 : 86 - 86
[28] CLINICAL ASSESSMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA SAMPLES FOR SOMATIC HYPERMUTATION STATUS BY NEXT-GENERATION SEQUENCING AND SANGER SEQUENCING
Arcila, M.
Huang, Y.
Hutt, K.
Panganiban, J.
Baldi, T.
Nafa, K.
Thornes, J.
Miller, J. E.
Klass, M.
HAEMATOLOGICA, 2015, 100 : 53 - 53
[29] Systematic Evaluation of Sanger Validation of Next-Generation Sequencing Variants
Beck, Tyler F.
Mullikin, James C.
Biesecker, Leslie G.
CLINICAL CHEMISTRY, 2016, 62 (04) : 647 - 654
[30] BLOCker-Sequencing: the next step from Sanger
不详
PHARMACOGENOMICS, 2011, 12 (05) : 705 - 705

← 1 2 3 4 5 →